|
| |
Dynavax TechnologiesDynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Our clinical development pipeline includes: HEPLISAV™, a hepatitis B vaccine in Phase 3 clinical trials; TOLAMBA™, a ragweed allergy immunotherapeutic; a hepatitis B therapy in a Phase 1 trial; and a cancer therapy for non-Hodgkin's lymphoma (NHL) in a Phase 2 trial and for metastatic colorectal cancer in a Phase 1 trial. Our preclinical program in asthma and chronic obstructive pulmonary disease (COPD) is partnered with AstraZeneca. Our preclinical work on an influenza vaccine is funded in part by the National Institutes of Health (NIH), while our colorectal cancer clinical trial and preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and Symphony provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization.
| Contact Details: |
| 2929 Seventh Street, Suite 100 |
| Berkeley |
| CA |
| 94710 |
| United States of America |
| Tel: | +1.510.848.5100 |
| Fax: | +1.510.848.1327 |
| Email: | contact@dynavax.com |
| WWW: | www.dynavax.com/
|
|
Loading...
|
Recent Publications by Dynavax Technologies: |  |
CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.
CpG-containing immunostimulatory DNA sequences (ISS), which signal through... | 3rd October, 2009
| Dynavax Technologies Corporation, Berkeley, California 94710, USA.
| J Clin Invest. 2009 Sep;119(9):2564-76. doi: 10.1172/JCI38294. Epub 2009
DOI Direct Link |
Development of TLR inhibitors for the treatment of autoimmune diseases.
SUMMARY: The innate immune system is a critical element of protection from... | 18th June, 2009
| Dynavax Technologies Corporation, Berkeley, CA 94710, USA.
| Immunol Rev. 2008 Jun;223:271-83.
DOI Direct Link |
Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs.
Efforts to develop therapeutic approaches based on stimulation of... | 23rd May, 2009
| Dynavax Technologies, Berkeley, CA 94710, USA.
| Methods Mol Biol. 2009;517:415-40.
DOI Direct Link |
Chemical modification of viruses and virus-like particles.
Protein capsids derived from viruses may be modified by methods,... | 11th March, 2009
| Dynavax Technologies Corp., Berkeley, CA 94710-2753, USA.
| Curr Top Microbiol Immunol. 2009;327:1-21.
|
Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications.
Plasmacytoid dendritic cells (PDC) are highly specialized immune cells... | 16th January, 2009
| Dynavax Technologies Corporation, Berkeley, CA 94710, USA.
| J Intern Med. 2009 Jan;265(1):43-57.
DOI Direct Link |
→View more Dynavax Technologies research publications. |
Press Releases on Dynavax Technologies:
|
 |
| Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA |
28th April, 2009 |
BeaconEquity.com |
DALLAS, April 28 /PRNewswire/ -- BeaconEquity.com announces the availability of Stock Alerts on stocks making news today. As the influenza dominates the headlines, several biopharmaceutical stocks are
|
| Symphogen Appoints New Medical Advisory Board And Scientific Advisory
|
1st May, 2005 |
Symphogen |
Symphogen Appoints New Medical
Advisory Board And Scientific Advisory Board Member
Copenhagen,
Denmark, 25 May 2005:
Symphogen A/S announced today that it has appointed a new, world
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 494 times since April 2007, the link to the organisation's website has been followed 88 times Search for more companies in Berkeley Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Dynavax Technologies |
